|
Contents |
|
|
|
|
|
|
Glioblastoma
|
|
|
|
Fabian
Baumann, Miroslava Bjeljac, Spyros S. Kollias, Brigitta G. Baumert,
Sebastian Brandner, Valentin Rousson, Yasuhiro Yonekawa, René L. Bernays
Combined Thalidomide and Temozolomide Treatment in Patients with
Glioblastoma Multiforme
Journal of Neuro-Oncology, 67 (1-2): 191-200, March, 2004 - April, 2004 (Abstract+)
|
|
M.
Bjeljac, F. Baumann and R. Bernays
Combined
thalidomide and temozolomide treatment in patients with glioblastoma multiforme
39th
ASCO Annual Meeting. Chicago, IL. May 31-June 3, 2003.
Abstract No. 451
|
|
J.
N. Capparella, V. M. Johnson, X. Maestri-Moden, P. Sampath, N. Ready,
L. Alderson
Phase II trial of daily oral temozolomide
and thalidomide in newly diagnosed glioblastoma multiforme before
radiation therapy
39th ASCO Annual Meeting.
Chicago, IL. May 31-June 3, 2003. Abstract No.
483
|
|
Jo
Glass, Gruber Michael , Anit Nirenberg
Phase I/II Study of Carboplatin and Thalidomide in
Recurrent Glioblastoma Multiforme
ASCO
Proceedings, 1999 Annual Meeting, Abstract
No.
551
|
|
Morris D. Groves, Vinay K. Puduvalli,
Susan M. Chang, Charles A. Conrad, Mark R. Gilbert,
Ivo W. Tremont-Lukats, Ta-Jen Liu, Pamela Peterson, David Schiff,
Timothy F. Cloughesy, Patrick Y. Wen, Harry Greenberg,
Lauren E. Abrey, Lisa M. DeAngelis, Kenneth R. Hess,
Kathleen R. Lamborn, Michael D. Prados and W. K. Alfred Yung
A North American brain tumor consortium (NABTC 99-04) phase II trial of
temozolomide plus thalidomide for recurrent glioblastoma multiforme
J Neurooncol. 2006 Sep 22; [Epub
ahead of print]
Abstract
|
|
|
Kesari
S, Schiff D, Henson JW, Muzikansky A, Gigas DC, Doherty L, Batchelor TT,
Longtine JA, Ligon KL, Weaver S, Laforme A, Ramakrishna N, Black PM,
Drappatz J, Ciampa A, Folkman J, Kieran M, Wen PY.
Phase II study of temozolomide, thalidomide, and celecoxib for newly
diagnosed glioblastoma in adults
Neuro Oncol. 2008 Apr 10; [Epub ahead of print]
Abstract |
DBLinks | BL 7:8
|
|
Marx GM,
Pavlakis N, McCowatt S, Boyle FM, Levi JA, Bell DR, Cook R, Biggs M, Little N,
Wheeler HR
Phase II study of thalidomide in the treatment of
recurrent glioblastoma multiforme
J Neurooncol 2001 Aug;54(1):31-8 (Abstract+)
|
|
|
Surasak Phuphanich
Recurrent
Multicentric Glioblastoma Multiforme Responds to Thalidomide and
Chemotherapy
Oncology, Vol 16, No 3 (March 2002), Letter to the
Editor
Abstract |
Full Text | 
Reprint |
DBLinks | BL 1:1
|
|
|
Puduvalli VK, Giglio P, Groves MD, Hess KR,
Gilbert MR, Mahankali S, Jackson EF, Levin VA, Conrad CA, Hsu SH, Colman H,
de Groot JF, Ritterhouse MG, Ictech SE, Yung WK
Phase II trial of irinotecan and thalidomide in adults with recurrent
glioblastoma multiforme
Neuro Oncol. 2008 Feb 26; [Epub ahead of print]
Abstract |
DBLinks | BL 7:6
|
|
Christopher D. Turner, Susan Chi,
Karen J. Marcus, Tobey MacDonald, Roger J. Packer, Tina Young Poussaint,
Sridhar Vajapeyam, Nicole Ullrich, Liliana C. Goumnerova, R. Michael Scott,
Caitlin Briody, Christine Chordas, Mary Ann Zimmerman and
Mark W. Kieran
Phase II study of thalidomide and radiation in children with newly diagnosed
brain stem gliomas and glioblastoma multiforme
J Neurooncol. 2006 Sep 22; [Epub
ahead of print]
Abstract
|
|
|
Gliomas
|
|
|
|
W.
Adler, F. C. Lee
A
phase I trial using combination irinotecan and thalidomide for recurrent CNS
tumors
39th
ASCO Annual Meeting. Chicago, IL. May 31-June 3, 2003.
Abstract No. 489
|
|
T. Ahmed, B. Chen,
G. Rabbani, M. N. Wallam and D. Benzil
Phase II trial of thalidomide (TD), tamoxifen
(TX), and temozolomide (T) for patients with advanced malignant gliomas (MG)
2005
ASCO Annual Meeting. Orlando, FL. May 13-17. Abstract No. 1575
Journal of Clinical Oncology, Vol 23, No 16S (June 1 Supplement),
2005: 1575
|
|
|
A. Desjardins, J. A. Quinn, D. A.
Reardon, J. N. Rich, J. J. Vredenburgh, C. Efird, H. S. Friedman
Phase II study of thalidomide and daily
cyclophosphamide for adults with malignant glioma
40th
ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1554
|
|
|
Fine HA, Kim L, Albert PS, Duic JP, Ma H, Zhang
W, Tohnya T, Figg WD, Royce C
A phase I trial of lenalidomide in patients with recurrent primary
central nervous system tumors
Clin Cancer Res. 2007 Dec 1;13(23):7101-6
Abstract |
DBLinks | BL 7:1
|
|
Fine HA,
Wen PY, Maher EA, Viscosi E, Batchelor T, Lakhani N, Figg WD, Purow BW, Borkowf
CB
Phase
II trial of thalidomide and carmustine for patients with recurrent high-grade
gliomas
J Clin Oncol. 2003 Jun 15;21(12):2299-304
|
|
H.
A. Fine, L. Kim, C. Royce, J. P. Duic, L. J. Cohen, S. Mitchell
A
phase I trial of CC-5103, a potent thalidomide analog, in patients with
recurrent high-grade gliomas and other refractory CNS malignancies
39th ASCO Annual Meeting.
Chicago, IL. May 31-June 3, 2003. Abstract No.
418
|
|
Fine
HA, Figg WD, Jaeckle K, Wen PY, Kyritsis AP, Loeffler JS, Levin VA, Black
PM, Kaplan R, Pluda JM, Yung WK
Phase II trial of
the antiangiogenic agent thalidomide in patients with recurrent high-grade
gliomas
J Clin
Oncol 2000 Feb;18(4):708-15 (PDF Full Text)
|
|
HA
Fine, JS Loeffler, A Kyritsis, P Wen, PM Black, VA Levin, S Graham, WKA Yung
A phase II trial of the anti-angiogenic agent,
thalidomide, in patients with recurrent high-grade gliomas
ASCO
Proceedings, 1997 Annual Meeting, Abstract No. 1372
|
|
|
M. Gelati, E. Corsini, S. Frigerio, B. Pollo, G. Broggi,
D. Croci, A. Silvani, A. Boiardi, A. Salmaggi
Effects
of Thalidomide on Parameters Involved in Angiogenesis: An in vitro
Study
Journal of Neuro-Oncology, 64 (3): 193-201, September 2003
|
|
Short
SC, Traish D, Dowe A, Hines F, Gore M, Brada M
Thalidomide
as an anti-angiogenic agent in relapsed gliomas
J Neurooncol. 2001 Jan;51(1):41-5. (Abstract+)
|
|
|
Hemangioblastoma
|
|
|
|
Maria Piribauer,
Thomas Czech, Karin Dieckmann, Peter Birner,
Johannes A. Hainfellner, Daniela
Prayer, Barbara Fazeny-Dörner, Georg Weinländer
and
Christine Marosi
Stabilization of a progressive hemangioblastoma under
treatment with thalidomide
Journal
of Neuro-Oncology 66: 295–299, February
2004.(Abstract+)
|
|
|
Metastatic Tumors
|
|
|
| |
Myriam
W Ben Arush, Sergey Postovsky, Ronit Elhasid, A Ben-Barak, C Levine,
Joseph F Guilburd
Antiangiogenic therapy
in pediatric malignancies: experience of the Northern Israel Pediatric Cancer
Center
ASCO Proceedings, 2002
Annual Meeting, Abstract No. 2926
|
|
Hwu WJ, Lis E, Menell JH, Panageas KS, Lamb LA, Merrell J, Williams LJ,
Krown SE, Chapman PB, Livingston PO, Wolchok JD, Houghton AN
Temozolomide plus thalidomide in patients with brain
metastases from melanoma
Cancer.
2005 Apr 28; [Epub ahead of print]
|
|
|
Knisely JPS, Berkey B, Chakravarti A, Yung AW,
Curran Jr WJ, Robins HI, Movsas B, Brachman DG, Henderson RH, Mehta MP
A Phase III Study of Conventional Radiation Therapy Plus Thalidomide
versus Conventional Radiation Therapy for Multiple Brain Metastases (RTOG
0118)
Int
J Radiat Oncol Biol Phys. 2008 Jan 3; [Epub ahead of print]
Abstract |
DBLinks | BL 7:3
|
|
J.
P. Knisely, B. A. Berkey, A. Chakravarti, W. A. Yung, W. J. Curran, H.
I. Robins, B. Movsas, D. G. Brachman, R. H. Henderson, M. P. Mehta
RTOG 0118: A Phase III
Study of Conventional Radiation Therapy Alone vs. Conventional Radiation
Therapy Plus Thalidomide for Multiple Brain Metastases
2005
ASCO Annual Meeting. Orlando, FL. May 13-17. Abstract No. 1500.
Journal of Clinical Oncology,
Vol 23, No 16S (June 1 Supplement), 2005: 1500
|
|
|
Tumors
|
|
|
|
Belo
AV, Barcelos LS, Teixeir MM, Ferreira MA, Andrade SP.
Differential effects
of antiangiogenic compounds in neovascularization, leukocyte recruitment,
VEGF production, and tumor growth in mice.
Cancer
Invest. 2004;22(5):723-9
|
|
|
Chaudhry
V, Cornblath DR, Corse A, Freimer M, Simmons-O'Brien E, Vogelsang G
Thalidomide-induced
neuropathy
Neurology
2002 Dec 24;59(12):1872-5
|
|
Verheul
HM, Panigrahy D, Yuan J, D'Amato RJ
Combination
oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth
in rabbits
Br J
Cancer 1999 Jan;79(1):114-8
|
bottom
|
